<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345228</url>
  </required_header>
  <id_info>
    <org_study_id>R347/05/2004</org_study_id>
    <nct_id>NCT00345228</nct_id>
  </id_info>
  <brief_title>Myopic Macular Haemorrhages</brief_title>
  <official_title>Myopic Macular Haemorrhages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore National Eye Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <brief_summary>
    <textblock>
      1. To identify the underlying causes of macular haemorrhages in patients with high myopia&#xD;
&#xD;
        2. In the eyes found to have macular haemorrhages secondary to choroidal&#xD;
           neovascularisation, we hope to identify the risk factors for the development of&#xD;
           choroidal neovascularisation in high myopia&#xD;
&#xD;
        3. To study the functional outcome of these eyes as assessed by visual acuity&#xD;
&#xD;
        4. To study the morphological outcome of these eyes by clinical assessment (and fundal&#xD;
           photography) and fluorescein angiography&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aims&#xD;
&#xD;
        -  To identify the underlying aetiologies of macular haemorrhages in myopic eyes&#xD;
&#xD;
        -  To study the functional and morphological outcome of these eyes with macular&#xD;
           haemorrhages 6 months later Secondary Aims&#xD;
&#xD;
        -  To study the subgroup of eyes with myopic choroidal neovascularisation (CNV), in&#xD;
           particular the risk factors for CNV in myopes&#xD;
&#xD;
        -  To study the subgroup of eyes with macular haemorrhages in the absence of CNV&#xD;
&#xD;
      Plan of investigation:&#xD;
&#xD;
        1. Patient with myopia (&gt;-6.00DS) presents with loss of central vision&#xD;
&#xD;
        2. Examination reveals a macular haemorrhage&#xD;
&#xD;
        3. Investigations&#xD;
&#xD;
             -  Refraction&#xD;
&#xD;
             -  Axial length*&#xD;
&#xD;
             -  Fundus fluorescein angiography&#xD;
&#xD;
             -  Indocyanine green angiography*&#xD;
&#xD;
        4. Determine if a myopic CNV is present or absent&#xD;
&#xD;
        5. Management of patient: Treatment vs No treatment&#xD;
&#xD;
             -  Treatment being&#xD;
&#xD;
                  1. Conventional laser&#xD;
&#xD;
                  2. PDT&#xD;
&#xD;
        6. Review at 6 months&#xD;
&#xD;
             -  BCVA&#xD;
&#xD;
             -  Clinical appearance (fundal photo)&#xD;
&#xD;
             -  FFA&#xD;
&#xD;
        7. Review at 12 months&#xD;
&#xD;
             -  BCVA&#xD;
&#xD;
             -  Clinical appearance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>December 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Myopic Macular Haemorrhages</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High myopia (greater than -6.00DS)&#xD;
&#xD;
          -  Macular haemorrhage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular haemorrhages from other causes eg. diabetic retinopathy, hypertensive&#xD;
             retinopathy&#xD;
&#xD;
          -  Allergy to fluorescein or indocyanine green dyes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-Yen Lee, FRCSEd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore National Eye Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong-Lye Ang, FRCOphth</last_name>
    <role>Study Chair</role>
    <affiliation>Singapore National Eye Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2004</verification_date>
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>June 26, 2006</last_update_submitted>
  <last_update_submitted_qc>June 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2006</last_update_posted>
  <keyword>High myopia</keyword>
  <keyword>Choroidal neovascularisation</keyword>
  <keyword>Lacquer crack</keyword>
  <keyword>Fundus fluorescein angiography</keyword>
  <keyword>Indocyanine green angiography</keyword>
  <keyword>Axial length</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

